CELLEGY TO STOP HIV TRANSMISSION STUDY IN GHANA

Cellegy Pharmaceuticals Inc. (CLGY.O: Quote, Profile, Research) on Tuesday said it will stop a late-stage study of its vaginal gel on preventing HIV infection in Ghana because of a lower-than-expected rate of transmission of the virus. Cellegy said the lower rate was possibly due in part to counseling on HIV prevention and the distribution of condoms.

Reuters (http://today.reuters.com/investing/financeArticle.aspx?type=governmentFilingsNews&storyID=URI:urn:newsml:reuters.com:20051108:MTFH97705_2005-11-08_13-55-42_WEN3879:1)